Onconetix, Inc. (NASDAQ:ONCO) Short Interest Update

Onconetix, Inc. (NASDAQ:ONCO) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 623,400 shares, a decline of 15.6% from the March 15th total of 738,300 shares. Based on an average trading volume of 9,300,000 shares, the short-interest ratio is currently 0.1 days. Approximately 6.6% of the shares of the stock are short sold.

Onconetix Trading Up 0.7 %

ONCO stock opened at $0.05 on Tuesday. The business’s 50 day moving average is $0.19 and its 200-day moving average is $1.14. Onconetix has a 1-year low of $0.05 and a 1-year high of $21.40.

Hedge Funds Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Millennium Management LLC acquired a new position in Onconetix, Inc. (NASDAQ:ONCO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 39,477 shares of the company’s stock, valued at approximately $25,000. Millennium Management LLC owned approximately 0.48% of Onconetix as of its most recent filing with the Securities and Exchange Commission (SEC). 23.89% of the stock is owned by hedge funds and other institutional investors.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.